Mounjaro Beat Trulicity in Trial Outcomes
The FDA approval was based mostly on outcomes cardiovascular outcomes with Mounjaro and Trulicity (dulaglutide), in a trial involving greater than 13,000 adults with sort 2 diabetes and established atherosclerotic heart problems who had been adopted for a median of 4 years.
The outcomes of the trial show “significant threat discount,” in response to Marilyn Tan, MD, medical professor of drugs, endocrinology, gerontology and metabolism at Stanford Drugs in Palo Alto, California, who was not concerned within the drug improvement.
Will the FDA Motion Enhance Insurance coverage Protection for Mounjaro?
Whether or not this new FDA motion will change insurance coverage protection stays to be seen.
“This new indication could enhance and/or increase insurance coverage protection for such medicines, however GLP-1 agonists stay pricey, so it’s in the end as much as the person insurance policy on how they supply protection,” says Dr. Tan.
